Journals / Genel Tıp Dergisi / 2017 / Cilt: 27 - Sayı: 3

Omeprazol ve gliklazid ilaç etkileşimine bağlı hipoglisemi olgusu

Pages
106–108
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A case of an 82-year-old diabetic patient who developed hypoglycemia secondary to a drug interaction of omeprazole and gliclazide.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Patients with diabetes mellitus frequently use prescription or nonprescription proton pump inhibitors (PPI) since they commonly have dyspeptic complaints.
📊
Key Findings & Data:Simultaneous use of various drug groups due to presence of different diseases in the same patient increases the risk of drug-to-drug interaction and change of drug effect secondary to decreased cytochrome p450 enzyme activity, especially in elderly patients.
💡
Conclusion & Impact:A case of an 82-year-old diabetic patient who developed hypoglycemia secondary to a drug interaction of omeprazole and gliclazide.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Patients with diabetes mellitus frequently use prescription or nonprescription proton pump inhibitors (PPI) since they commonly have dyspeptic complaints. Simultaneous use of various drug groups due to presence of different diseases in the same patient increases the risk of drug-to-drug interaction and change of drug effect secondary to decreased cytochrome p450 enzyme activity, especially in elderly patients. A case of an 82-year-old diabetic patient who developed hypoglycemia secondary to a drug interaction of omeprazole and gliclazide.

Özet

Dispeptik yakınmaların sık görülmesi nedeniyle diyabet hastaları reçeteli ya da reçetesiz olarak proton pompa inhibitörleri (PPİ) grubu ilaçları sık olarak kullanırlar. Farklı hastalıklar nedeniyle çeşitli ilaç gruplarının bir arada kullanılması, azalan sitokrom p450 enzim aktivitesi nedeniyle özellikle yaşlı hastalarda, ilaç-ilaç etkileşimi ve ilaç etkisinin değişmesi riskini artırmaktadır. Bu vaka sunumunda 82 yaşında diyabetik hastada omeprazol ve gliklazid ilaç etkileşimine bağlı gelişen hipoglisemi olgusu sunuldu.

🔖

Cite This Article

BALDANE, S., İPEKÇİ, S. H., KEBAPCILAR, L. (2017). Omeprazol ve gliklazid ilaç etkileşimine bağlı hipoglisemi olgusu. Genel Tıp Dergisi, Cilt: 27 - Sayı: 3, 106–108. https://ajindex.com/articles/166055

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Boj-Carceller D. Proton pump inhibitors: impact on glucose metabolism. Endocrine 2013;43:22-32
  2. Mefford IN, Wade EU. Proton pump inhibitors as a treatment method for type II diabetes. Med Hypotheses 2009;73:29-32
  3. Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, et al. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes 2011;2:217-20
  4. Crouch MA, Mefford IN, Wade EU. Proton pump inhibitör therapy associated with lower glycosylated hemoglobin le vels in type 2 diabetes. J Am Board Fam 2012;25:50-4
  5. Phadatare PD, Chandrashekhar VM. Influence of esomeprazole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits. Mol Cell Biochem 2011;354:135-40
  6. Kumar V, Venakat Rao N, Ramachandra Setty S. Influence of omeprazole on hypoglycemic activity of glibenclamide and tolbutamide normal albino rabbits. Acta Pharm Turc 2000;42:135-8.